论文部分内容阅读
慢性粒细胞白血病(CML)是累及造血系统干细胞的恶性肿瘤,具有典型的两或三阶段病程,慢性期平均3.5年,传统药物(马利兰、羟基脲)不能阻止疾病急变,也不能明显延长病人生存期。近20年来该病的治疗手段和策略有较大进展,现综述如下。 1 化疗 1.1 单一药物疗法,即传统的常规疗法:①羟基脲(HU):为细胞周期特异性DNA合成抑制剂。剂量通常为20～50mg/kg.d,分次口服,维持剂量使白细胞低于20×10~9/L,由于具有同时降低白细胞及血小板、缩小脾脏的作用,而且作
Chronic myeloid leukemia (CML) is a malignant tumor involving hematopoietic stem cells and has a typical two- or three-stage disease course. In the chronic phase, an average of 3.5 years, CML can not prevent the rapid change of disease and prolong the survival of patients period. The past 20 years the treatment of disease and strategies have made great progress, are summarized below. 1 chemotherapy 1.1 single drug therapy, the traditional conventional therapy: ① hydroxyurea (HU): a cell cycle-specific inhibitor of DNA synthesis. Dosage is usually 20 ~ 50mg / kg.d, oral sub-level to maintain the dose of leukocytes less than 20 × 10 ~ 9 / L, due to the same time reduce the white blood cells and platelets, reduce the role of the spleen,